MISOORA is entering the U.S. market on June 22 with a five-step biotech skincare regimen built around two high-profile actives — NAD+ (nicotinamide adenine dinucleotide) and retinaldehyde — positioning the line squarely at the intersection of cellular longevity science and prestige K-Beauty formulation. The brand opened a founding-member waitlist on June 5, signaling a direct-to-consumer launch strategy with aspirations beyond the supplement aisle into the fast-growing topical-bioactive channel.
NAD+ has accumulated significant clinical interest as a coenzyme central to mitochondrial function and DNA repair. While oral NAD+ precursors such as NMN and NR have dominated the longevity supplement category, topical delivery remains a formulation challenge — bioavailability through the stratum corneum is limited, and brands must carefully substantiate any structure-function claims to avoid drug-claim territory under FDA guidelines. Retinaldehyde, a retinoid one oxidative step removed from retinoic acid, is generally regarded as offering efficacy closer to prescription tretinoin while maintaining an over-the-counter safety profile, making it a technically sophisticated anchor for a consumer-facing regimen.
The global nutricosmetics market — encompassing both ingestible and topical bioactive beauty products — is on a sustained upward trajectory, driven by consumer demand for science-backed, mechanism-first product narratives rather than traditional anti-aging marketing language. MISOORA's explicit pivot to "longevity" framing over "anti-aging" mirrors a broader industry shift tracked across finished formulation launches in the past 18 months, as brands align messaging with the cellular-health vocabulary that has gained traction in the functional foods and nutraceuticals space. The beauty-from-within and topical convergence trend has opened co-formulation and white-label opportunities for ingredient suppliers operating across both categories.
Details on clinical endpoint data, standardized extract specifications, active concentrations in mg/serving equivalents, or third-party peer-reviewed validation for the MISOORA regimen have not been disclosed ahead of launch. Operators and formulators evaluating the line for potential retail or co-manufacturing partnerships will want to scrutinize the brand's evidentiary framework — particularly any structure-function claims tied to NAD+ topical delivery — before committing shelf or formulation space. As scrutiny of longevity-positioned products intensifies at both the FDA and FTC levels, substantiation depth will be a differentiating factor in a crowded market.
Powered by Food & Beverage Magazine, Functional News will continue tracking MISOORA's U.S. retail distribution strategy and any clinical data disclosures following the June 22 debut.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.